Xilio Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
3. Fair Value Measurements
Liabilities measured at fair value on a recurring basis consist of the following as of March 31, 2026:
| Quoted | ||||||||
|---|---|---|---|---|---|---|---|---|
| Prices in | ||||||||
| Active · Significant | ||||||||
| Markets for · Other · Significant | ||||||||
| Identical · Observable · Unobservable | ||||||||
| Assets · Inputs · Inputs | ||||||||
| Level 1 · Level 2 · Level 3 · Total | ||||||||
| Financial liabilities: | ||||||||
| Series A warrants to purchase common stock | $ | — | $ | — | $ | 20,560 | $ | 20,560 |
| Series C warrants to purchase common stock | — | — | 5,700 | 5,700 | ||||
| Total financial liabilities at March 31, 2026 | $ | — | $ | — | $ | 26,260 | $ | 26,260 |
Liabilities measured at fair value on a recurring basis consist of the following as of December 31, 2025:
| Quoted | ||||||||
|---|---|---|---|---|---|---|---|---|
| Prices in | ||||||||
| Active · Significant | ||||||||
| Markets for · Other · Significant | ||||||||
| Identical · Observable · Unobservable | ||||||||
| Assets · Inputs · Inputs | ||||||||
| Level 1 · Level 2 · Level 3 · Total | ||||||||
| Financial liabilities: | ||||||||
| Series A warrants to purchase common stock | $ | — | $ | — | $ | 23,100 | $ | 23,100 |
| Series C warrants to purchase common stock | — | — | 6,460 | 6,460 | ||||
| Total financial liabilities at December 31, 2025 | $ | — | $ | — | $ | 29,560 | $ | 29,560 |
The fair value of the common stock warrant liabilities, which are described in more detail in Note 8, are calculated utilizing a Black-Scholes option pricing model for the Series A warrants and a Monte Carlo simulation model for the Series C warrants. The Black-Scholes option pricing model and the Monte Carlo simulation model both require the use of assumptions, certain of which are not observable in the market, which represent Level 3 measurements within the fair value hierarchy. The Black-Scholes pricing model and the Monte Carlo simulation model assumptions include the warrant exercise price, the expected term of the warrant, the current price of the Company’s common stock, expected volatility, the risk-free interest rate for the expected term of the warrant and expected dividend yield. The Monte Carlo simulation assumptions also include the potential impacts of the warrant strike price reset features.
The following assumptions were used in determining the fair value of the Company’s common stock warrant liabilities as of March 31, 2026 and December 31, 2025:
| March 31, · December 31, | |||||||
|---|---|---|---|---|---|---|---|
| 2026 · 2025 | |||||||
| Closing price of common stock | $ | 8.41 | $ | 8.96 | |||
| Warrant exercise price | $ | 10.50 | $ | 10.50 | |||
| Expected volatility | 70 | % | 70 | % | |||
| Risk free interest rate | 3.79 | % | 3.62 | % | |||
| Expected dividend yield | — | — | |||||
| Expected term (in years) | 0.67 - 4.18 | 0.92 - 4.43 | |||||
The following table summarizes the changes in the fair market value of the Company’s common stock warrant liabilities, which are classified within the Level 3 fair value hierarchy:
| financial | ||||||
|---|---|---|---|---|---|---|
| Series A · Series C · liabilities | ||||||
| Balance at December 31, 2025 | $ | 23,100 | $ | 6,460 | $ | 29,560 |
| Change in fair value of common stock warrant liabilities | (2,540) | (760) | (3,300) | |||
| Balance at March 31, 2026 | $ | 20,560 | $ | 5,700 | $ | 26,260 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.